Viridian Therapeutics, Inc. VRDN Proceeds From Issuance Of Warrants
Proceeds From Issuance Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfWarrants.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s proceeds from issuance of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s proceeds from issuance of warrants?
- Viridian Therapeutics, Inc. (VRDN) reported proceeds from issuance of warrants of $0 in Q1 2026.
- How has Viridian Therapeutics, Inc.'s proceeds from issuance of warrants changed year-over-year?
- Viridian Therapeutics, Inc.'s proceeds from issuance of warrants decreased by 100.0% year-over-year, from $1.62M to $0.
- What does proceeds from issuance of warrants mean?
- This represents the cash proceeds received by the company upon the issuance or exercise of warrants, which grant holders the right to purchase company stock at a specified price. It reflects an alternative method of raising capital that can provide liquidity while potentially impacting future share dilution. Investors track this to evaluate the company's ongoing ability to secure funding through equity-linked instruments.